As per reports, it has been revealed that U. S. stocks were found to be trading quite high in the market. While to cite an example it has been found that the stocks gained 11.7 points in the Standard & Poor's 500-stock index.

In addition, it has been revealed that a lot many concerns have been raised by the U. S. drug reviewers about the drug Kynamro, which is being produced by the Sanofi SA as well as by Isis Pharmaceuticals. The reviewers expressed their concerns on the FDA’s website, and affirmed that people, who have been taking the medicine, are facing certain health complications.

There are a number of factors like rise in heart and liver damages. Such complications have made a number of people from not to take the medicine. "This higher incidence of cancer raises the specter that the FDA may require another trial for Kynamro's approval”, said Kimberly Lee, who is an analyst at ThinkEquity.

The news has led to a decline in the shares of Isis Pharmaceuticals Inc and its hares have toppled by 21%. The reviewers also affirmed that though the medicine is effective in curbing cholesterol, its health concerns are such that the medicine needs to be reassessed.